Literature DB >> 19401359

Contemporary treatment principles for early rheumatoid arthritis: a consensus statement.

Patrick D W Kiely1, Andrew K Brown, Christopher J Edwards, David T O'Reilly, Andrew J K Ostör, Mark Quinn, Allister Taggart, Peter C Taylor, Richard J Wakefield, Philip G Conaghan.   

Abstract

OBJECTIVE: RA has a substantial impact on both patients and healthcare systems. Our objective is to advance the understanding of modern management principles in light of recent evidence concerning the condition's diagnosis and treatment.
METHODS: A group of practicing UK rheumatologists formulated contemporary management principles and clinical practice recommendations concerning both diagnosis and treatment. Areas of clinical uncertainty were documented, leading to research recommendations.
RESULTS: A fundamental concept governing treatment of RA is minimization of cumulative inflammation, referred to as the inflammation-time area under the curve (AUC). To achieve this, four core principles of management were identified: (i) detect and refer patients early, even if the diagnosis is uncertain: patients should be referred at the first suspicion of persistent inflammatory polyarthritis and rheumatology departments should provide rapid access to a diagnostic and prognostic service; (ii) treat RA immediately: optimizing outcomes with conventional DMARDs and biologics requires that effective treatment be started early-ideally within 3 months of symptom onset; (iii) tight control of inflammation in RA improves outcome: frequent assessments and an objective protocol should be used to make treatment changes that maintain low-disease activity/remission at an agreed target; (iv) consider the risk-benefit ratio and tailor treatment to each patient: differing patient, disease and drug characteristics require long-term monitoring of risks and benefits with adaptations of treatments to suit individual circumstances.
CONCLUSION: These principles focus on effective control of the inflammatory process in RA, but optimal uptake may require changes in service provision to accommodate appropriate care pathways.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19401359     DOI: 10.1093/rheumatology/kep073

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  21 in total

Review 1.  Can Rheumatologists Predict Eventual Need for Orthopaedic Intervention in Patients with Rheumatoid Arthritis? Results of a Systematic Review and Analysis of Two UK Inception Cohorts.

Authors:  Elena Nikiphorou; Lewis Carpenter; Sam Norton; Stephen Morris; Alex MacGregor; Josh Dixey; Peter Williams; Patrick Kiely; David Andrew Walsh; Adam Young
Journal:  Curr Rheumatol Rep       Date:  2017-03       Impact factor: 4.592

2.  Review of a rheumatology triage system: simple, accurate, and effective.

Authors:  Thirza Carpenter; Steven J Katz
Journal:  Clin Rheumatol       Date:  2013-11-01       Impact factor: 2.980

3.  Prostacyclin regulates bone growth via the Epac/Rap1 pathway.

Authors:  Michele R Hutchison; Perrin C White
Journal:  Endocrinology       Date:  2014-11-18       Impact factor: 4.736

4.  Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment.

Authors:  L T C van Hulst; W Kievit; R van Bommel; P L C M van Riel; L Fraenkel
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-10       Impact factor: 4.794

5.  Evaluation of work disability in Japanese patients with rheumatoid arthritis: from the TOMORROW study.

Authors:  Shohei Anno; Yuko Sugioka; Kentaro Inui; Masahiro Tada; Tadashi Okano; Kenji Mamoto; Tatsuya Koike
Journal:  Clin Rheumatol       Date:  2018-03-10       Impact factor: 2.980

6.  Induction with Infliximab and a Plant-Based Diet as First-Line (IPF) Therapy for Crohn Disease: A Single-Group Trial.

Authors:  Mitsuro Chiba; Tsuyotoshi Tsuji; Kunio Nakane; Satoko Tsuda; Hajime Ishii; Hideo Ohno; Kenta Watanabe; Mai Ito; Masafumi Komatsu; Takeshi Sugawara
Journal:  Perm J       Date:  2017

Review 7.  Diagnostic value of anti-cyclic citrullinated peptide antibody for rheumatoid arthritis in a Chinese population: a meta-analysis.

Authors:  Fei Gao; Lei Ren; Cai-Qin Zhang; Feng-Yun Mu; Yan-Qiu You; Yan-Hong Liu
Journal:  Rheumatol Int       Date:  2011-09-30       Impact factor: 2.631

8.  Looking through the 'window of opportunity': is there a new paradigm of podiatry care on the horizon in early rheumatoid arthritis?

Authors:  James Woodburn; Kym Hennessy; Martijn Pm Steultjens; Iain B McInnes; Deborah E Turner
Journal:  J Foot Ankle Res       Date:  2010-05-17       Impact factor: 2.303

9.  Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience.

Authors:  H Singh; V Gupta; S Ray; H Kumar; P Talapatra; M Kaur; S Kumar; S Arya; R Mathur; N Ghangas
Journal:  Clin Rheumatol       Date:  2012-09-15       Impact factor: 2.980

Review 10.  Outcome measures in inflammatory rheumatic diseases.

Authors:  Jaap Fransen; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.